Study Links Prenatal Cannabis Exposure To Schizophrenia – New Telegraph
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchMental HealthPediatricsNeurologyTHCSafetyCannabis Why This Matters I don't see a summary provided in…
Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia
A novel clinical trial is investigating tDCS cannabis use disorder schizophrenia treatment, targeting specific brain circuits involved in addiction and cognitive control. This innovative approach addresses the challenging dual diagnosis where traditional…
Cannabis use patterns in first episode psychosis and schizophrenia: A scoping review and case series.
Cannabis use is associated with psychosis development and symptom relapse in persons with schizophrenia spectrum disorders (SCZ). As U.S. states legalize can...
Phenome-Wide Associations of Polygenic Scores for Schizophrenia and Major Depression in 100,000 Chinese Adults.
China faces significant mental health challenges, with unique associations between mental disorders and other traits observed in its population. Based on sum...
Envisioning Cannabinoid CB1 Receptor Biased Signaling as a Therapeutic Target for Schizophrenia.
The relationship between the endocannabinoid system and the emergence and treatment of schizophrenia-related symptoms continues to be a topic of significant ...
Prevalence of schizophrenia spectrum and bipolar disorder among patients with cannabis induced psychosis: a systematic review and meta-analysis.
Distinguishing cannabis-induced psychosis from primary psychiatric disorders is difficult and has significant clinical and prognostic implications. Current t...
Endocannabinoid System and Psychotic Disorders: Clinical
Clinical Takeaway Cannabis-induced psychosis frequently precedes diagnosis of schizophrenia spectrum or bipolar disorder, with patients requiring careful long-term psychiatric monitoring rather than reassurance about symptom resolution. The overlap…
Endocannabinoid System and Psychosis Risk: Clinical Evidence
Clinical Takeaway Cannabis-induced psychosis increases the risk of subsequently developing schizophrenia spectrum and bipolar disorder, with prevalence rates varying significantly across studies. Patients experiencing cannabis-induced psychosis require…
Endocannabinoid System Psychosis Risk: Clinical Research Guide
Clinical Takeaway Clinical Takeaway Patients presenting with cannabis-induced psychosis have measurable risk for developing schizophrenia spectrum or bipolar disorder, though distinguishing these primary psychiatric conditions from acute cannabis effects…
Endocannabinoid System Clinical Research on Psychosis Risk
Clinical Takeaway Patients who experience cannabis-induced psychosis have a documented risk of subsequently developing schizophrenia spectrum or bipolar disorder, with prevalence varying across studies due to differences in follow-up duration and…